Sobi to trim staff as Pfizer manufacturing contract ends early
March 24, 2022As biotech retreats, gene therapy companies retrench and redraw plans
March 24, 2022The approval of Pluvicto for prostate cancer is a notable step forward for the filed of radiopharmaceutical therapy and validates the Swiss drugmaker's $2.1 billion buyout of Endocyte in 2018.
